Expert Interviews

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

OT Roundup debuts with new ADHD ocular findings, a surgeon's own trifocal IOL journey, MOGENRY's FDA filing, and myopia policy news.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Adam Muzychuk, MD, discusses how AI like the Kane formula is improving outcomes, and why he still urges caution over relying on it for clinical decisions.

Hove explains how his own cataract surgery has changed the way he counsels patients about glare, halos, and near vision.

Jai Parekh, MD, MA, FAAO, says AI is poised to transform eye care—from retinal and glaucoma imaging to cataract surgery—without disrupting it.

Radhika Rampat, MBBS, FRCOphth, discusses how AI is already shaping intraocular lens selection and keratoconus screening, and where anterior segment imaging and patient-facing AI tools are headed next.

At ESCRS 2026, Adam Muzychuk, MD, shares real-world data showing the enVista Envy IOL matches clinical trial outcomes, even in eyes with residual refractive error.

Two-year data presented at ESCRS 2026 show the ELIOS excimer laser procedure sustained IOP reduction and kept most glaucoma patients medication-free.

A prospective French study found intraoperative OCT most valuable for measuring key surgical distances in deep sclerectomy and MIGS procedures, and useful for training residents.

ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.

Three-year ESCRS 2026 data show trans-epithelial PRK matches conventional PRK in refractive outcomes, safety, and pain, with faster surgical time.

A real-world study of an enhanced monofocal IOL found most patients achieved 20/20 distance vision and functional intermediate vision without glasses, according to Jai Parekh, MD, MA, FAAO, at ESCRS 2026.

New ESCRS 2026 data show corneal measurements shift meaningfully across the day, with early-morning readings potentially biased by overnight eyelid closure.

At ESCRS 2026 in London, Radhika Rampat, MBBS, FRCOphth, describes bringing low-level light therapy into her refractive practice, from dry eye care to chalazion treatment and pre-surgical ocular surface optimisation.

Suzana Konjevoda, MD, presents data at ESCRS 2026 showing citicoline eye drops aid corneal nerve recovery post-cataract surgery.

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s

Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.

Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.

Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed doses in wet AMD.

John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging therapies including a C1q inhibitor and cell-based options.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now.

At WIO 2026, Durga Borkar, MD, discussed DAVIO2 trial results for EYP-1901 in wet AMD.

Dante Pieramici, MD, discusses EYP-1901, a sustained-delivery tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 JAK/STAT signaling, in the phase 3 COMO and CAPRI diabetic macular edema trials.